I thought I would give you the benefit of the doubt but you truely do not have a grasp of business and what is going on here. |
Thought they'd smack this down big time this morning with the wider market mayhem.
Surprisingly resilient at the MO. |
Posters on LSE are working overtime on this share. |
Thiopia. If you are benchmarking against AZN…
Revenue $51b
Value $200b
So 400% of revenues
AGL revenue £3m
So £12m market cap
Gotta compare like with like! |
Well anyone waiting on the sidelines, now is the buying opportunity! |
I think we need to add a zero to AGL Market Cap just to allow for the fact they are playing with the Big Boys now
AGL - Mkt Cap £50m
ILMN - Mkt Cap $20Bn
AZN - Mkt Cap $200Bn
free stock charts from uk.advfn.com |
As agreed with Bones, re visit the subject at the start of the 2nd half. |
Yazx you were doing the same placing scream when this was 8p. I remember your FUD. Many quotes available |
Patt may have a point, there may be a fundraise coming later this year but if the share can keep this upwards trajectory hopefully it won't be too dilutive and also with the rapid progress being made it may be the last one.
Also everyone seems to have forgotten that they are nearly 3 years into a 5 year trial with an NHS teaching hospital for prostate cancer where the lead researcher hypothesised Parsortix could become the standard of care for patients.
If that is a success it may only be 4 or 5 years before that becomes reality |
If i were a holder? You're an idiot. Wasting your Sunday on here with no holding.Move on.Exciting news will develop next week with Illumina and my bet Astrazeneca will get more involved. Still holding out for an offer from them. |
radders
I would take what he says with a large pinch of salt
A couple of weeks ago he showed up suggesting people should buy into STX
He was ramping STX in October when it was 5p
Then came a 3p placing and it fell as low as 2.2p
PATT is not a serious person let alone investor
sent from my iPhone |
Totally agree Bermudashorts. PATT’s rather dismissive comment “it is just more theorising from colleagues…221; entirely misses the point. |
I fully agree. It is very exciting but remember that everybody said that Abbotts would buy AGL out as soon as FDA clearance was obtained. It is always soon to be oh so exciting. The bald facts are that unless this turns into £ or $ contract pretty soon the excitement will rapidly disappear just like all the previous ones have. But there is always a chance it is this time. Maybe! |
 radders,
Just to add to your post, the main EACR conference is their Annual Congress which was held in Rotterdam last year. Illumina sponsored a symposium at that conference - 'More to see with liquid biopsy'.
You can download Illumina's flyer 'Highlights at EACR 2024' from the link below and you'll see that there was a joint session with Angle's Anne-Sophie Pailhes-Jimenez and Illumina's Dr Anna Babayan and Dr Vincent Stevens. So both companies jointly presenting. They also mention Angle's poster on the flyer.
Worth noting that 3 days ago Illumina's Dr Babayan posted the following on linkedin:-
'So excited about this study done by ANGLE!
A dual workflow for CTC and ctDNA molecular characterisation using the same workflow allows truly unbiased comparison of the two major liquid biopsy analytes without compromising insights. This was highly needed to further deepen our knowledge about compelemetarity of the two analytes and maximize information we get from liquid biopsy analyses. Congrats to the ANGLE team! '
Clearly a very close and collaborative relationship. |
PATT, in an earlier post, you described the Illumina analysis as “interesting but far from any commercial application. It is just more theorising from colleagues who have worked together on this for years”.
However, when it comes to the dual ctDNA/CTC analysis, the first RNS on this subject was released just over a year ago (January 4, 2024). The critical distinction with Wednesday’s announcement is that, for the first time, they have published results using an actual Illumina panel. Or, to quote from the RNS “a workflow using, for the first time, an end-to-end Illumina solution for analysis.” Previously, the data results released were based on a third-party panel from NuProbe.
This is significant because, as AN explained to me on the day of the AGM, “what Illumina would obviously prefer is to use their DNA panel on their sequencer, because then they would be getting all of the revenues, not just a significant part of the revenues.” Illumina has a clear commercial interest in supporting this dual analysis, and the RNS refers to the webinar as being the “first joint marketing initiative for ANGLE and Illumina.”
This undoubtedly represents a major milestone for the company, and I look forward to learning more details. |
Illumina could buy this lot with some loose change... |
Actually it would be the biggest possible vindication of the tech. If Illumina bought in the share price would fly. |
NON-DILUTIVE FUNDING POTENTIAL
I would also repeat that recently FAB a £4m cap got £6m from UK Govt Future Medicines Initiative
The Labour Government wants to encourage growth
Why not throw money at a World leading technology validated by UK Global Pharma AstraZeneca and US Global DNA diagnostics firm Illumina ?
Now is the time for UK Government to provide stimulus which will have massive MULTIPLIER effects for Jobs, GDP and Growth as well as huge Health benefits
free stock charts from uk.advfn.com |
That makes no sense whatsoever. Why would that be any different to a placing - except existing holders wouldn't be able to avoid dilution - it would actually be worse than a placing! |
If Illumina took an equity stake ( vía an issue of new shares ) then there would be no need for a placing. |
Indeed - let's leave it there and keep it on topic. Should be an interesting few months ahead. |
Krypton,
Indeed.
Nigel,
Based on his input on Apta he has no idea when it comes to assessment of value. He does not understand a balance sheet, financial statements, formal announcements, business strategy etc - nothing. All he does is excerpt some figures from a results announcement, misconstrues the same (deliberately or inadvertently) then shouts placing/administration. When his thesis is repudiated he does not respind and continues to persist posting the same comment indefinitely asking posters to respond - the cycle continues.
Angle will likely need a placing at some point this year and I have so opined previously. However, it could conceivably at any point announce the next phase of the AZ deal or a partnership with Illumina that could lead to the shares doubling overnight. zIf it were to do a placing at say, 25p, I doubt current buyers would be disenchanted.
Anyway, that is the last comment from me on that clown.
Back to Angle. |
Nigelpm. Just forget about trying to justify yourself. The morons have no interest in anything but hate and vindictiveness. Woe betide anybody who suggests that things may not be as they seem. |
If his track record is anything to go by we're looking at a 200% rise from here
sent from my iPhone |
I didn't say he was a serious investor and I have no idea what he does in his spare time - my reference was simply to the evidence I had seen before my eyes of his posts on the POLX board which were spot on. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
